Drug Profile
Rufloxacin
Alternative Names: Chiriax; MF-934; Monos; Qari; Rufakin; TebraxinLatest Information Update: 10 Jul 2007
Price :
$50
*
At a glance
- Originator Mediolanum
- Developer Bracco; Hilton Pharma; Laboratoires Leurquin-Mediolanum; Selvi Laboratorio Bioterapico; Universal Pharma Holdings
- Class Antibacterials; Fluoroquinolones; Small molecules
- Mechanism of Action DNA gyrase inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bacterial infections; Respiratory tract infections; Urinary tract infections
Most Recent Events
- 10 Jul 2007 Discontinued - Phase-III for Bacterial infections in United Kingdom (PO)
- 10 Jul 2007 Discontinued - Phase-III for Bacterial infections in USA (PO)
- 06 Dec 2001 Registered for Bacterial infections in South Korea (PO)